 Home > Active Ingredient News > Study of Nervous System > Eli Lilly and MiNA develop a new drug based on the saRNA platform, Bojian and Ca...

Eli Lilly and MiNA develop a new drug based on the saRNA platform, Bojian and Ca...

 Last Update: 2021-05-23
 Source: Internet
 Author: User

Tags

gamma 1 2

dmt research

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

CompileKe Ke

On May 11, Eli Lilly and MiNA Therapeutics, an RNA activation therapy company, announced a global research collaboration to develop new drug candidates using MiNA's proprietary small molecule activated RNA (saRNA) technology platform.

According to the terms of the agreement, MiNA will use its saRNA platform to research five targets selected by Eli Lilly, aimed at addressing diseases in Lilly's key therapeutic areas.

At the same time, Biogen and Capsigen also announced that they have reached a strategic research cooperation to design a new adeno-associated virus (AAV) capsid, which may provide transformative gene therapy to solve the problem.

As part of the collaboration, Capsigen’s patented TRADE™ platform and related technologies will be used to create and identify new AAV capsids to meet disease-specific transduction profiles.

Under the terms of the agreement, Capsigen will apply its vector engineering methods to develop new capsids to meet highly customized disease-specific transduction profiles.

Reference source:

2.
Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Scopolamine hot sale CAS 51-34-3 wholesale Scopolamine powder

CAS No.: 51-34-3

Pharmacy Grade

$3.2-3.5/KG FOB

Paroxetine CAS 61869-08-7

CAS No.: 61869-08-7

Pharmacy Grade

$88-98/KG FOB

Scopolamine Hydrobromide CAS 114-49-8

CAS No.: 114-49-8

Pharmacy Grade

$118-128/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.